Products
Manfidokimab Biosimilar Monoclonal Antibody (IL-4Rα) for Research
Pre-Made Manfidokimab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-680-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Manfidokimab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody |
| INN Name | Manfidokimab |
| Target | IL4R |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | na |
| Companies | Akeso Biopharma |
| Conditions Approved | na |
| Conditions Active | Atopic dermatitis |
| Conditions Discontinued | na |
| Development Tech | na |
About target - IL4R
1. Protein Interleukin-4 receptor subunit alpha
2. Gene IL4R
3. Organism Homo sapiens (Human)
Function
Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.
Soluble IL4R (sIL4R) inhibits IL4-mediated cell proliferation and IL5 up-regulation by T-cells.
